Skip to main content
Thorax logoLink to Thorax
. 1997 Feb;52(2):185–186. doi: 10.1136/thx.52.2.185

Decreased exhaled nitric oxide in subjects with HIV infection

M O Loveless, C R Phillips, G D Giraud, W E Holden
PMCID: PMC1758484  PMID: 9059483

Abstract

BACKGROUND: Nitric oxide (NO) may be an important component of the host defence against infections. Endogenously produced NO is present in exhaled air and may be representative of respiratory tract production of NO. Since subjects infected with HIV are prone to develop respiratory infections, it was postulated that exhaled NO might be reduced in such individuals. METHODS: The exhaled concentration of NO (nl/l) and minute ventilation (l/min) were measured and exhaled NO release (nl/min/m2) calculated in 36 subjects infected with HIV (20 non- smokers, 16 smokers) and 31 non-smoking subjects with no active medical conditions. RESULTS: Exhaled NO from HIV positive individuals was less than from control subjects of similar age, height, and weight. Cigarette smoking did not account for the decreased exhaled NO in HIV positive individuals as both smoking and non-smoking HIV positive subjects had decreased exhaled NO compared with control subjects. CONCLUSION: Exhaled NO is decreased in subjects infected with the HIV. Since NO functions in host defence against bacterial, viral, and fungal infections, reduced exhaled NO may indicate a mechanism of impaired host defence in HIV infection. 




Full Text

The Full Text of this article is available as a PDF (92.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dinh-Xuan A. T., Higenbottam T. W., Clelland C. A., Pepke-Zaba J., Cremona G., Butt A. Y., Large S. R., Wells F. C., Wallwork J. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991 May 30;324(22):1539–1547. doi: 10.1056/NEJM199105303242203. [DOI] [PubMed] [Google Scholar]
  2. Gerlach H., Rossaint R., Pappert D., Knorr M., Falke K. J. Autoinhalation of nitric oxide after endogenous synthesis in nasopharynx. Lancet. 1994 Feb 26;343(8896):518–519. doi: 10.1016/s0140-6736(94)91465-6. [DOI] [PubMed] [Google Scholar]
  3. Gustafsson L. E., Leone A. M., Persson M. G., Wiklund N. P., Moncada S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun. 1991 Dec 16;181(2):852–857. doi: 10.1016/0006-291x(91)91268-h. [DOI] [PubMed] [Google Scholar]
  4. Kharitonov S. A., Yates D., Robbins R. A., Logan-Sinclair R., Shinebourne E. A., Barnes P. J. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994 Jan 15;343(8890):133–135. doi: 10.1016/s0140-6736(94)90931-8. [DOI] [PubMed] [Google Scholar]
  5. Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109–142. [PubMed] [Google Scholar]
  6. Persson M. G., Zetterström O., Agrenius V., Ihre E., Gustafsson L. E. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet. 1994 Jan 15;343(8890):146–147. doi: 10.1016/s0140-6736(94)90935-0. [DOI] [PubMed] [Google Scholar]
  7. Petitpretz P., Brenot F., Azarian R., Parent F., Rain B., Herve P., Simonneau G. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation. 1994 Jun;89(6):2722–2727. doi: 10.1161/01.cir.89.6.2722. [DOI] [PubMed] [Google Scholar]
  8. Yates D. H., Kharitonov S. A., Robbins R. A., Thomas P. S., Barnes P. J. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am J Respir Crit Care Med. 1995 Sep;152(3):892–896. doi: 10.1164/ajrccm.152.3.7663801. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES